Dietary supplement

Research Group Patents New Vitamin for Health and Well-Being

Retrieved on: 
Wednesday, January 11, 2023

LODA, Ill., Jan. 11, 2023 (GLOBE NEWSWIRE) -- A private research group has secured a U.S. patent for a newly discovered vitamin.

Key Points: 
  • LODA, Ill., Jan. 11, 2023 (GLOBE NEWSWIRE) -- A private research group has secured a U.S. patent for a newly discovered vitamin.
  • Vitamin MePiA is the second of two new vitamins that have been patented by this group, Aardsma Research and Publishing, located in the small town of Loda, IL.
  • The full patent may be read here: https://www.biblicalchronologist.org/store/MePiA-Patent-US-2021.PDF
    Gerald Aardsma, Ph.D., has dedicated his life to independent research work.
  • I hope people will educate themselves about my work, so they can take appropriate action for their health and well-being."

Volunteer Botanicals’ Satival Cannabinoid Powders Demonstrate Potential in Clinical Study

Retrieved on: 
Tuesday, January 10, 2023

Directed by Vanderbilt University Medical Center-trained Dr. Jacob H. Basham, the study concluded that the Satival plant-based powders demonstrated a significant increase in activation within these key genes, supporting the overwhelming feedback received from consumers.

Key Points: 
  • Directed by Vanderbilt University Medical Center-trained Dr. Jacob H. Basham, the study concluded that the Satival plant-based powders demonstrated a significant increase in activation within these key genes, supporting the overwhelming feedback received from consumers.
  • “This study shows without question that no longer is there just anecdotal reports of Satival powders generating a biological effect,” said Derek Odette, chief executive officer at Volunteer Botanicals.
  • Developed by Volunteer Botanicals, Satival pharmaceutical-grade powder supplement ingredients are available for the nutraceutical market.
  • “Further research needs to be conducted on the impacts of cannabinoids, but the results of this study show that plant-based supplements are headed in the right direction,” Odette said.

Consumers Love VUE™ Vitamin-Infused Teas and Powder Packs - Join the Movement to Introduce a “Better for You” Functional Health Beverage

Retrieved on: 
Tuesday, January 10, 2023

“We are giving people another option besides many of the sugar and additive-filled beverages currently on the market,” shares VUE™ CEO Kenton Gray.

Key Points: 
  • “We are giving people another option besides many of the sugar and additive-filled beverages currently on the market,” shares VUE™ CEO Kenton Gray.
  • “We created VUE™ to help everyone feel and perform at their best, every day.
  • bottles) - in Boston and Miami, where the brand hosted several mid-year events focused on health, wellness, and fitness.
  • The team will also host additional lifestyle and health events around the country to continue promoting a national movement toward improved wellness.

Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors

Retrieved on: 
Tuesday, January 10, 2023

ACTOnco is intended for use by healthcare professionals to help them inform clinical management decisions in accordance with professional guidelines for cancer patients with solid tumors.

Key Points: 
  • ACTOnco is intended for use by healthcare professionals to help them inform clinical management decisions in accordance with professional guidelines for cancer patients with solid tumors.
  • This is the first and only Asia-based company to receive FDA clearance for a comprehensive genomic profiling test.
  • ACT Genomics is the first biotech company in Asia that received market authorization for a cancer comprehensive genomic profiling assay.
  • With this incredible milestone achieved, we will continuously promote precision medicine in Asia and our company mission to turn genomics into action.”

Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea

Retrieved on: 
Tuesday, January 10, 2023

The Phase 3 clinical trials are part of a collaboration with Dr. Reddy’s Laboratories Ltd. for the ongoing development and commercialization of the DFD-29 program.

Key Points: 
  • The Phase 3 clinical trials are part of a collaboration with Dr. Reddy’s Laboratories Ltd. for the ongoing development and commercialization of the DFD-29 program.
  • The MVOR-01 and MVOR-02 clinical trials are randomized in a 3:3:2 ratio to DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg), Oracea® (Doxycycline capsules 40 mg) or placebo once daily for 16 weeks.
  • The secondary objective is to evaluate the safety, efficacy and tolerability of DFD-29 compared to Oracea® (Doxycycline capsules 40 mg).
  • Additional information on the DFD-29 Phase 3 clinical trial program can be found on ClinicalTrials.gov using the identifiers: NCT05296629 and NCT05343455 .

Floré and DSM Partner to Revolutionize Probiotics Sector

Retrieved on: 
Tuesday, January 10, 2023

Floré is a later-stage startup involved in gut health and personal nutrition, using patented whole-genome DNA sequencing and gut composition analysis to formulate personalized probiotics to an individual’s unique gut microflora.

Key Points: 
  • Floré is a later-stage startup involved in gut health and personal nutrition, using patented whole-genome DNA sequencing and gut composition analysis to formulate personalized probiotics to an individual’s unique gut microflora.
  • DSM backs startups in this area with a focus on personalization and precision that can transform health, nutrition and bioscience.
  • In return, DSM will help Floré source high-quality ingredients for its products, and take advantage of DSM’s deep knowledge base and extensive business network.
  • “Investors are increasingly placing their bets on the disruptive potential of custom probiotics, and we knew a strategic partnership with Floré would be mutually beneficial,” said Pieter Wolters, managing director of DSM Venturing.

BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing Rules

Retrieved on: 
Monday, January 9, 2023

Accordingly, the Company has regained compliance with the Nasdaq Listing Rule 5550(a)(2) and the bid price deficiency matter as previously disclosed is now closed.

Key Points: 
  • Accordingly, the Company has regained compliance with the Nasdaq Listing Rule 5550(a)(2) and the bid price deficiency matter as previously disclosed is now closed.
  • In addition, on January 4, 2023, the Company received a Foreign Delinquency Compliance Plan Alert Letter (the “Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”).
  • The Letter has no immediate effect on the listing or trading of the Company’s ordinary shares on Nasdaq.
  • The Company’s management is working diligently to complete the Filing as soon as practicably possible to regain compliance with the Nasdaq Listing Rule 5250(c)(2).

Inozyme Pharma Announces Investor and Analyst Event and Highlights 2022 Progress

Retrieved on: 
Monday, January 9, 2023

BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will share topline pharmacokinetic, pharmacodynamic (PK/PD) and safety data from the ongoing Phase 1/2 clinical trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency at a virtual Investor and Analyst Event on Thursday, Feb. 16, 2023.

Key Points: 
  • We also saw promising PPi elevation in our ABCC6 Deficiency trial, with a rapid initial increase at the lowest dose of INZ-701.
  • The Company will share topline pharmacokinetic, pharmacodynamic (PK/PD) and safety data from ongoing Phase 1/2 trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency.
  • The event will also feature presentations from members of the Inozyme management team, as well as from key opinion leaders in ENPP1 Deficiency and ABCC6 Deficiency.
  • The webcast will be accessible through the Investor Relations section of Inozyme’s website under events and will be available for a limited time following the event.

Derm-Biome Pharmaceuticals’ Multi-Target Topical Drug Produces Positive Results in Preclinical Study in Acne

Retrieved on: 
Monday, January 9, 2023

The psychological impact of acne is substantial, causing profound negative social effects on the quality of life.

Key Points: 
  • The psychological impact of acne is substantial, causing profound negative social effects on the quality of life.
  • There are currently no satisfactory treatments for acne that combine high efficacy and acceptable safety.
  • The global acne treatment market size is forecast to reach as high as $16.9B USD by 2030 (Precedence Research).
  • We feel that it has significant potential to be a first-line treatment for acne and atopic dermatitis, two inflammatory skin diseases with substantial unmet need.”

Collagen Supplement Global Market Report 2022: Rising Awareness of Health Benefits Drives Adoption - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023

The global collagen supplement market size reached US$ 2.06 Billion in 2021.

Key Points: 
  • The global collagen supplement market size reached US$ 2.06 Billion in 2021.
  • Besides this, the rising awareness among the masses about the benefits of collagen supplements to prevent collagen deficiency in the body is contributing to the growth of the market.
  • This, along with the growing utilization of collagen supplements in the food and beverage (F&B) industry, is offering a positive market outlook.
  • The publisher provides an analysis of the key trends in each sub-segment of the global collagen supplement market report, along with forecasts at the global, regional and country level from 2022-2027.